Identification of Cys255 in HIF‐1α as a novel site for development of covalent inhibitors of HIF‐1α/ARNT PasB domain protein–protein interaction

The heterodimer HIF‐1α (hypoxia inducible factor)/HIF‐β (also known as ARNT‐aryl hydrocarbon nuclear translocator) is a key mediator of cellular response to hypoxia. The interaction between these monomer units can be modified by the action of small molecules in the binding interface between their C‐terminal heterodimerization (PasB) domains. Taking advantage of the presence of several cysteine residues located in the allosteric cavity of HIF‐1α PasB domain, we applied a cysteine‐based reactomics “hotspot identification” strategy to locate regions of HIF‐1α PasB domain critical for its interaction with ARNT. COMPOUND 5 was identified using a mass spectrometry‐based primary screening strategy and was shown to react specifically with Cys255 of the HIF‐1α PasB domain. Biophysical characterization of the interaction between PasB domains of HIF‐1α and ARNT revealed that covalent binding of COMPOUND 5 to Cys255 reduced binding affinity between HIF‐1α and ARNT PasB domains approximately 10‐fold. Detailed NMR structural analysis of HIF‐1α‐PasB‐COMPOUND 5 conjugate showed significant local conformation changes in the HIF‐1α associated with key residues involved in the HIF‐1α/ARNT PasB domain interaction as revealed by the crystal structure of the HIF‐1α/ARNT PasB heterodimer. Our screening strategy could be applied to other targets to identify pockets surrounding reactive cysteines suitable for development of small molecule modulators of protein function.

[1]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[2]  D. Fattori,et al.  Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.

[3]  K. Gardner,et al.  Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet interface for hetero- and homodimerization. , 2005, Journal of molecular biology.

[4]  H. Jhoti,et al.  Fragment-based drug discovery using rational design. , 2007, Ernst Schering Foundation symposium proceedings.

[5]  P. Ratcliffe,et al.  Regulation of HIF: prolyl hydroxylases. , 2006, Novartis Foundation symposium.

[6]  G. Semenza HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.

[7]  Scott B Ficarro,et al.  A structure-guided approach to creating covalent FGFR inhibitors. , 2010, Chemistry & biology.

[8]  James B. Mitchell,et al.  PX‐478, an inhibitor of hypoxia‐inducible factor‐1α, enhances radiosensitivity of prostate carcinoma cells , 2008, International journal of cancer.

[9]  R. Hammer,et al.  The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.

[10]  M. Westergaard,et al.  A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth , 2008, Molecular Cancer Therapeutics.

[11]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[12]  David Baker,et al.  Quantitative reactivity profiling predicts functional cysteines in proteomes , 2010, Nature.

[13]  A. Harris,et al.  Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions , 2012, Expert opinion on therapeutic targets.

[14]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[15]  J F Brandts,et al.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter. , 1989, Analytical biochemistry.

[16]  H. Dyson,et al.  Homodimerization of the PAS-B domains of hypoxia-inducible factors. , 2012, The journal of physical chemistry. B.

[17]  S. McKnight,et al.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.

[18]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[19]  J. H. Ward Hierarchical Grouping to Optimize an Objective Function , 1963 .

[20]  D. Kufe,et al.  Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179* , 2006, Journal of Biological Chemistry.

[21]  Zhaobin Zhang,et al.  Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. , 2005, Cancer research.

[22]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[23]  Erwin G. Van Meir,et al.  Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. , 2011, Journal of medicinal chemistry.

[24]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[25]  Kevin H. Gardner,et al.  Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor , 2009, Proceedings of the National Academy of Sciences.

[26]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[27]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[28]  Olof Ramström,et al.  Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.

[29]  D. Kufe,et al.  Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. , 2006, The Journal of biological chemistry.

[30]  M. Yoshimura,et al.  Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels , 2012, Nature Communications.

[31]  V. Haase The VHL tumor suppressor: master regulator of HIF. , 2009, Current pharmaceutical design.

[32]  K. Gardner,et al.  Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[34]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[35]  Lei Zhang,et al.  Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor* , 2005, Journal of Biological Chemistry.

[36]  Valerie Daggett,et al.  Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B. , 2009, Journal of the American Chemical Society.

[37]  G. Semenza Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[38]  M. Konopleva,et al.  A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[41]  M. Konopleva,et al.  A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells , 2006, Clinical Cancer Research.

[42]  N. Foloppe The benefits of constructing leads from fragment hits. , 2011, Future medicinal chemistry.

[43]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[44]  Yate-Ching Yuan,et al.  Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. , 2011, ACS chemical biology.

[45]  Y. Soh,et al.  Rapid degradation of hypoxia‐inducible factor‐1α by KRH102053, a new activator of prolyl hydroxylase 2 , 2008, British journal of pharmacology.